Improvements in US breast cancer survival and proportion explained by tumor size and estrogen-receptor status

Journal of Clinical Oncology

Volumn 33, Issue 26, 2015, Pages 2870-2876

  Park, Ju Hyun ^a   Anderson, William F ^b   Gail, Mitchell H ^b  

^a Dongguk University   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; MORTALITY RATE; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VOLUME; UNITED STATES; BREAST TUMOR; CANCER REGISTRY; CHEMISTRY; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; SEER PROGRAM;

EID: 84958826817     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.9191     Document Type: Article

References (38)

1. Hermon C, Beral V: Breast cancer mortality rates are levelling off or beginning to decline in many western countries: Analysis of time trends, agecohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer 73:955-960, 1996
2. Peto R, Boreham J, Clarke M, et al: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355:1822, 2000
3. Blot WJ, Devesa SS, Fraumeni JF Jr: Declining breast cancer mortality among young American women. J Natl Cancer Inst 78:451-454, 1987
4. Tarone RE, Chu KC: Implications of birth cohort patterns in interpreting trends in breast cancer rates. J Natl Cancer Inst 84:1402-1410, 1992
5. National Cancer Institute: SEER∗Stat Database: Incidence, SEER 9 Regs Research Data, Nov 2012 Sub (1973-2010), Katrina/Rita Population Adjustment, Linked to County Attributes, Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission, 2013. www.seer.cancer.gov
6. National Cancer Institute: SEER∗Stat Database: Incidence, SEER 18 Regs Research Data - Hurricane Katrina Impacted Louisianna Cases, Nov 2012 Sub (1973-2010 varying), Linked to County Attributes, Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission, 2013. www.seer.cancer.gov
7. Anderson WF, Katki HA, Rosenberg PS: Breast cancer incidence in the United States: Current and future trends. J Natl Cancer Inst 103:1397-1402, 2011
8. Swan J, Breen N, Graubard BI, et al: Data and trends in cancer screening in the United States: Results from the 2005 National Health Interview Survey. Cancer 116:4872-4881, 2010
9. American Cancer Society: Breast Cancer Facts & Figures 2013-2014. Atlanta, GA, American Cancer Society, 2014
10. Harlan LC, Abrams J, Warren JL, et al: Adjuvant therapy for breast cancer: Practice patterns of community physicians. J Clin Oncol 20:1809-1817, 2002
11. Harlan LC, Clegg LX, Abrams J, et al: Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 24:872-877, 2006
12. Anderson WF, Rosenberg PS, Petito L, et al: Divergent estrogen receptor-positive and-negative breast cancer trends and etiologic heterogeneity in Denmark. Int J Cancer 133:2201-2206, 2013
13. Consensus conference: Adjuvant chemotherapy for breast cancer. JAMA 254:3461-3463, 1985
14. NIH consensus conference: Treatment of early-stage breast cancer. JAMA 265:391-395, 1991
15. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30:5-15, 2001
16. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
17. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 1992
18. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 71-85, 1992
19. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352: 930-942, 1998
20. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
21. Berry DA, Inoue L, Shen Y, et al: Modeling the impact of treatment and screening on U.S. breast cancer mortality: A Bayesian approach. J Natl Cancer Inst Monogr 36:30-36, 2006
22. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
23. Munoz D, Near AM, van Ravesteyn NT, et al: Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst 106, 2014
24. Elkin EB, Hudis C, Begg CB, et al: The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer 104:1149-1157, 2005
25. National Cancer Institute: SEER∗Stat Database: Mortality, All COD, Aggregated With State, Total U.S. (1969-2010), Katrina/Rita Population Adjustment, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, underlying mortality data provided by NCHS (www.cdc.gov/nchs), 2013. www.seer.cancer.gov
26. Zelen M, Feinleib M: On the theory of screening for chronic diseases. Biometrika 56:601-614, 1969
27. Baker SG, Prorok PC, Kramer BS: Lead time and overdiagnosis. J Natl Cancer Inst 106, 2014
28. Gotzsche PC, Jorgensen KJ: Screening for breast cancer with mammography. Cochrane Database Syst Rev 6:CD001877, 2013
29. Shapiro S, Venet W, Strax P, et al: Ten-to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 69:349-355, 1982
30. Baum M: Survival and reduction in mortality from breast cancer. Impact of mammographic screening is not clear. BMJ 321:1470, 2000
31. Feuer EJ, Wun LM: How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol 136: 1423-1436, 1992
32. Forrest P: Breast Cancer Screening. Report to the Health Ministers of England, Wales, Scotland, and Northern Ireland. London, United Kingdom, Department of Health and Social Security, 1986
33. Autier P, Boniol M, Gavin A, et al: Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: Trend analysis of WHO mortality database. BMJ 343:d4411, 2011
34. Botha JL, Bray F, Sankila R, et al: Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 39:1718-1729, 2003
35. Jorgensen KJ, Zahl PH, Gotzsche PC: Breast cancer mortality in organised mammography screening in Denmark: Comparative study. BMJ 340:c1241, 2010
36. Tarone RE, Chu KC: The greater impact of menopause on ER- than ER+ breast cancer incidence: A possible explanation (United States). Cancer Causes Control 13:7-14, 2002
37. Anderson WF, Luo S, Chatterjee N, et al: Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat 113:189-196, 2009
38. Swan J, Breen N, Coates RJ, et al: Progress in cancer screening practices in the United States: Results from the 2000 National Health Interview Survey. Cancer 97:1528-1540, 2003